Doxycycline is a safe alternative to Hydroxychloroquine + Azithromycin to prevent clinical worsening and hospitalization in mild COVID-19 patients: An open label randomized clinical trial (DOXYCOV)
Sobngwi et al.,
Doxycycline is a safe alternative to Hydroxychloroquine + Azithromycin to prevent clinical worsening and..,
medRxiv, doi:10.1101/2021.07.25.21260838 (Preprint)
RCT 194 mild/asymptomatic low-risk patients in Cameroon, 97 treated with HCQ+AZ and 97 treated with doxycycline, showing 2.1% symptomatic patients at day 10 with HCQ+AZ, versus 4.3% with doxycycline, but without statistical significance. There were only 6 patients with symtoms at day 10. There was no mortality or hospitalization, and no major adverse events.
risk of no recovery, 51.6% lower, RR 0.48, p = 0.44, treatment 2 of 95 (2.1%), control 4 of 92 (4.3%), NNT 45, day 10.
|
risk of no recovery, 3.2% lower, RR 0.97, p = 1.00, treatment 18 of 95 (18.9%), control 18 of 92 (19.6%), NNT 162, day 3.
|
risk of no viral clearance, 3.2% lower, RR 0.97, p = 0.88, treatment 32 of 95 (33.7%), control 32 of 92 (34.8%), NNT 91, day 10.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Sobngwi et al., 29 Jul 2021, Randomized Controlled Trial, Cameroon, preprint, 16 authors, dosage 400mg days 1-5, this trial compares with another treatment - results may be better when compared to placebo.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.07.25.21260838; this version posted July 29, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .
Doxycycline is a safe alternative to Hydroxychloroquine + Azithromycin to
prevent clinical worsening and hospitalization in mild COVID-19 patients: An
open label randomized clinical trial (DOXYCOV)
Eugene Sobngwi1,2,3,4, Sylvain Zemsi1,3, Magellan Guewo-Fokeng2,3,4, Jean-Claude Katte2,3,
Charles Kounfack1,5, Liliane Mfeukeu-Kuate1,2, Armel Zemsi1, Yves Wasnyo1,3, Antoinette
Assiga Ntsama1, Arnaud Ndi-Manga1,3, Joelle Sobngwi-Tambekou3, William Ngatchou6,
Charlotte Moussi Omgba7, Jean Claude Mbanya1,2,4, Pierre Ongolo Zogo1,2,8, Pierre Joseph
Fouda1,2
1
Yaounde Central Hospital, Yaounde, Cameroon
2
Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon
3
RSD Institute, Yaounde, Cameroon
4
The Biotechnology Centre, University of Yaounde 1, Yaounde, Cameroon
5
Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon
6
Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon
7
Regional Delegation of Public Health, Centre Region, Ministry of Public Health, Cameroon
8
Center for the Development of Good Practices in Health, Yaounde, Cameroon
Corresponding author
Prof. Eugene Sobngwi
Department of Internal Medicine and Specialities, Faculty of Medicine and Biomedical Sciences,
University of Yaounde 1, Yaounde, Cameroon
Yaounde Central Hospital, and
RSD Institute, Yaounde, Cameroon
Email: eugene.sobngwi@fmsb-uy1.cm Tel : 675088750
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2021.07.25.21260838; this version posted July 29, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .
Abstract
Objective: We aimed to compare the safety and efficacy of a doxycycline-based regimen against
the national standard guidelines (Hydroxychloroquine plus Azithromycin) for the treatment of
mild symptomatic COVID-19.
Methods: We conducted an open-label, randomized, non-inferiority trial, in Cameroon
comparing Doxycycline 100mg, twice daily for 7 days versus Hydroxychloroquine, 400 mg daily
for 5 days and Azithromycin 500mg at day 1 and 250mg from day 2 through 5, in mild COVID19 patients. Clinical improvement, biological parameters and adverse events were assessed. The
primary outcome was the proportion of clinical cure at day 3, 10 and 30. Non-inferiority was
determined by the clinical cure rate between protocols with a 20 percentage points margin.
Results: 194 participants underwent randomization and were treated with Doxycycline (n=97) or
Hydroxychloroquine-Azithromycin (n=97). At day 3, 74/92 (80.4%) participants on Doxycycline
versus 77/95 (81.1%) on Hydroxychloroquine-Azithromycin -based protocols were asymptomatic
(p=0.91). At day 10, 88/92 (95.7%) participants on Doxycycline versus 93/95 (97.9%) on
Hydroxychloroquine-Azithromycin were asymptomatic (p=0.44). At day 30 all participants..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit